NCT07501897 Investigating the Impact of Cold Atmospheric Plasma Treatment on Wound Healing at Cannulation Sites in Patients Following Extracorporeal Life Support
| NCT ID | NCT07501897 |
| Status | Recruiting |
| Phase | — |
| Sponsor | National Taiwan University Hospital |
| Condition | ExtraCorporeal Life Support (ECLS) |
| Study Type | INTERVENTIONAL |
| Enrollment | 65 participants |
| Start Date | 2026-03-12 |
| Primary Completion | 2026-10-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 65 participants in total. It began in 2026-03-12 with a primary completion date of 2026-10-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to evaluate a new wound treatment called cold atmospheric plasma (CAP) for patients receiving extracorporeal life support (ECLS). Patients on extracorporeal life support (ECLS) often develop wounds at the sites where tubes are inserted, and these wounds can be difficult to heal and prone to infection. cold atmospheric plasma (CAP) is a gentle, non-heat treatment that can kill bacteria, reduce inflammation, and promote wound healing. In this study, patients will be randomly assigned to receive either standard wound care alone or standard care plus cold atmospheric plasma (CAP) treatment. Researchers will compare both groups to see whether cold atmospheric plasma (CAP) can reduce infection, improve healing speed, and decrease the need for additional procedures. The study will also monitor safety to ensure the treatment is well tolerated. The goal is to find a more effective and safe way to improve wound healing in critically ill patients.
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years * Receiving extracorporeal life support (ECLS) * Presence of cannulation site wound requiring wound care Exclusion Criteria: * Pre-existing severe dermatological conditions at the cannulation site * Severe coagulopathy precluding local intervention * Concurrent receipt of other experimental wound treatments * Life expectancy \< 48 hours
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07501897 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying ExtraCorporeal Life Support (ECLS). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07501897 currently recruiting?
Yes, NCT07501897 is actively recruiting participants. Contact the research team at chanchihyang@gmail.com for enrollment information.
Where is the NCT07501897 trial being conducted?
This trial is being conducted at Taipei, Taiwan.
Who is sponsoring the NCT07501897 clinical trial?
NCT07501897 is sponsored by National Taiwan University Hospital. The trial plans to enroll 65 participants.